Conference
Advertisement
Advertisement
Trending on Urology Times
1
Christof Vulsteke, MD, PhD, breaks down findings, implications of KEYNOTE-905
2
The UroOnc Minute: Active Surveillance for Intermediate-risk Prostate Cancer, with Michael Leapman, MD, MHS
3
The Significance of KEYNOTE-905 in Muscle-Invasive Bladder Cancer
4
Petros Grivas, MD, on the significance of a perioperative regimen for cisplatin-ineligible MIBC
5
